Neuralink’s secondary-market valuations have climbed sharply to the $42–60 billion range in recent months, up more than fourfold from the $9–9.7 billion post-money level set in its June 2025 Series E round that raised roughly $650 million. Private-market marks, including a $59.8 billion indication as of early October 2026, reflect sustained demand for shares amid limited primary financing and strong interest from investors drawn to Elon Musk’s ecosystem and the company’s progress in implantable brain-computer interfaces. Clinical activity remains early-stage, with roughly two dozen patients implanted and ongoing work on cursor control, vision restoration, and data collection, while broader brain-computer interface funding has diversified beyond Neuralink. With only weeks left until year-end, any additional secondary trades, regulatory updates, or trial expansions could influence near-term valuation marks before December 31.